Oncoimmunology
2021 Aug 17;10(1):1959102.
doi: 10.1080/2162402X.2021.1959102. eCollection 2021.
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
Yaru Feng 1, Xiuying Liu 1, Xiaorui Li 1, Yating Zhou 1, Zhiru Song 1, Jing Zhang 1, Bingjie Shi 1, Jianxun Wang 1 2
Affiliations expand
PMID: 34434610
PMCID: PMC8381848
DOI: 10.1080/2162402X.2021.1959102
Abstract
BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against multiple myeloma, yet antigen escape and tumor relapse still occur after the use of these therapies. Designing CAR-T therapies that targets multiple antigens simultaneously seems a feasible way to avoid antigen escape, and it has been extensively studied elsewhere. Here, we report novel BCMA-OR-CD38 Tan CAR T cells that can trigger robust cytotoxicity against target cells expressing either BCMA or CD38. We demonstrate that, in in vitro studies, these BCMA-OR-CD38 Tan CAR T cells exhibit similar CAR expression, superior cytotoxicity and antigen-stimulated T cell proliferation as compared to single-targeted CAR T cells or CD38-OR-BCMA Tan CAR T cells. Importantly, these BCMA-OR-CD38 Tan CAR-T cells can achieve complete tumor clearance in myeloma-bearing mice with no relapse observed through the course of these experiments. Finally, this BCMA-OR-CD38 Tan CAR was fully compatible with existing clinical grade T cell manufacturing procedures and can be implemented using current clinical protocols. Taken together, our results present an effective solution to the challenge of antigen escape in BCMA CAR T-cell therapies.
Keywords: BCMA CAR; CD38 CAR; Tandem-CAR T; antigen escape; multiple myeloma.
参考连接：
https://pubpeer.com/publications/9083EA5B87A8F167481F75AA97BD2A
本文为【丰倍SCI】公众号原创文章
未经授权禁止转载！
转载请勿更改原文内容及格式！
如有转载需求或合作事宜
可添加下方客服微信
或后台私信小编
三重保障：Al查重＋机械物理查重＋人工查重
官网：www.fengbei-ai.com
客服微信：sindy01010101
